# An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

> **NCT05887609** · PHASE2 · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 53 (estimated)

## Conditions studied

- Ovary Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Mirvetuximab Soravtansine-gynx
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT05887609
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-03
- **Primary completion:** 2029-01-31
- **Final completion:** 2031-01-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05887609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05887609, "An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05887609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*